A Network Pharmacology Study of Chinese Medicine QiShenYiQi to Reveal Its Underlying Multi-Compound, Multi-Target, Multi-Pathway Mode of Action

Xiang Li, Leihong Wu, Wei Liu, Yecheng Jin, Qian Chen, Linli Wang, Xiaohui Fan, Zheng Li, Yiyu ChengPLoS 2014 · DOI

Abstract

Traditional Chinese Medicine (TCM) is a complex system effective for chronic diseases, yet its modes of action (MOA) often remain elusive. This study investigates QiShenYiQi (QSYQ), a formula used for myocardial infarction (MI), through a systematic network pharmacology approach. By integrating transcriptomics from a rat MI model with network analysis, 55 potential targets were identified, 14 of which were previously linked to cardiovascular disease. Experimental validation focused on three sesquiterpenes from Dalbergia odorifera: Trans-nerolidol (ENL), SDL, and RDL. These compounds demonstrated anti-inflammatory effects by modulating ERK1/2, PPARγ, and HO-1 pathways. The resulting three-level compound-target-pathway network provides a comprehensive depiction of QSYQ's multi-faceted MOA in treating myocardial infarction.

Introduction

Traditional Chinese Medicine often relies on the synergistic effects of multiple compounds, making its "Mode of Action" (MOA) difficult to study using standard "one drug, one target" paradigms. QiShenYiQi (QSYQ), composed of Astragalus membranaceus, Salvia miltiorrhiza, Panax notoginseng, and Dalbergia odorifera, is widely used for cardiovascular conditions. However, the molecular crosstalk between its constituents and biological pathways has largely been a "black box." This study aims to bridge this gap using systems biology to visualize how QSYQ interacts with gene expression profiles in the context of myocardial infarction.

Methods

The researchers employed a three-tiered methodology:

  1. Transcriptomics: A rat model of MI was used to identify Differentially Expressed Genes (DEGs) in heart tissue following QSYQ treatment. Microarray data was deposited in GEO under accession GSE54134.
  2. Network Construction: Using the CHD@ZJU database and literature mining, main compounds were linked to DEGs. These were mapped to KEGG pathways using ArrayTrack and visualized via Cytoscape.
  3. Experimental Validation: Three sesquiterpenes—Trans-nerolidol (ENL), SDL, and RDL—were isolated from Dalbergia odorifera and tested on LPS-stimulated RAW264.7 macrophages to verify their anti-inflammatory effects.

Results and Discussion

The study identified a holistic network of 84 nodes, including 12 compounds, 55 genes, and 17 pathways. This confirms that QSYQ's efficacy emerges from distributed effects across immune, metabolic, and apoptotic pathways rather than a single molecule. Inflammation was identified as a central hub, with the gene RELA (an NF-κB subunit) influenced by nine different compounds.

Experimental Validation of Sesquiterpenes

To validate the network's predictions, the researchers focused on the anti-inflammatory properties of three specific sesquiterpenes. Initial tests confirmed that these compounds did not significantly impact cell viability at the concentrations used for testing, ensuring that subsequent results were not due to cytotoxicity.

Cell viability of RAW264.7 cells after treatment with varying concentrations of ENL, RDL, and SDL.

Subsequent assays showed that all three compounds significantly inhibited the production of nitrite, a key marker of inflammation, in LPS-stimulated macrophages. This provides direct evidence for the anti-inflammatory role of Dalbergia odorifera components within the QSYQ formula.

Inhibition of nitrite production by ENL, SDL, and RDL in LPS-stimulated macrophages.

Further molecular analysis revealed that ENL and SDL attenuated the pERK1/2 to ERK1/2 ratio and partially restored PPARγ expression. Additionally, all three compounds promoted the expression of Heme Oxygenase-1 (HO-1), a critical cardioprotective enzyme.

Conclusion

This study represents a significant step in moving TCM toward "precision systems pharmacology." By decoding the complex mechanism of QSYQ, the researchers have provided a blueprint for studying other multi-component traditional medicines. While future work should validate these findings in cardiomyocytes and explore synergistic interactions, this research highlights the power of integrating transcriptomics and network analysis to reveal the multi-target nature of complex therapies.

Summary updated

Abstract

Chinese medicine is a complex system guided by traditional Chinese medicine (TCM) theories, which has proven to be especially effective in treating chronic and complex diseases. However, the underlying modes of action (MOA) are not always systematically investigated. Herein, a systematic study was designed to elucidate the multi-compound, multi-target and multi-pathway MOA of a Chinese medicine, QiShenYiQi (QSYQ), on myocardial infarction. QSYQ is composed of Astragalus membranaceus (Huangqi), Salvia miltiorrhiza (Danshen), Panax notoginseng (Sanqi), and Dalbergia odorifera (Jiangxiang). Male Sprague Dawley rat model of myocardial infarction were administered QSYQ intragastrically for 7 days while the control group was not treated. The differentially expressed genes (DEGs) were identified from myocardial infarction rat model treated with QSYQ, followed by constructing a cardiovascular disease (CVD)-related multilevel compound-target-pathway network connecting main compounds to those DEGs supported by literature evidences and the pathways that are functionally enriched in ArrayTrack. 55 potential targets of QSYQ were identified, of which 14 were confirmed in CVD-related literatures with experimental supporting evidences. Furthermore, three sesquiterpene components of QSYQ, Trans-nerolidol, (3S,6S,7R)-3,7,11-trimethyl-3,6-epoxy-1,10-dodecadien-7-ol and (3S,6R,7R)-3,7,11-trimethyl-3,6-epoxy-1,10-dodecadien-7-ol from Dalbergia odorifera T. Chen, were validated experimentally in this study. Their anti-inflammatory effects and potential targets including extracellular signal-regulated kinase-1/2, peroxisome proliferator-activated receptor-gamma and heme oxygenase-1 were identified. Finally, through a three-level compound-target-pathway network with experimental analysis, our study depicts a complex MOA of QSYQ on myocardial infarction.
BibTeX
@inproceedings{li2014network,
  author = {Xiang Li and Leihong Wu and Wei Liu and Yecheng Jin and Qian Chen and Linli Wang and Xiaohui Fan and Zheng Li and Yiyu Cheng},
  title = {{A Network Pharmacology Study of Chinese Medicine QiShenYiQi to Reveal Its Underlying Multi-Compound, Multi-Target, Multi-Pathway Mode of Action}},
  booktitle = {PLoS},
  year = {2014},
  doi = {10.1371/journal.pone.0095004},
}
Figure